Oncology Research and Treatment

 

Morphologie, Immunhistochemie und Genetik peripherer T-Zellen-Lymphome

Lennert K.a · Feller A.C.a · Gödde-Salz E.a

Author affiliations

aAbteilung für Pathologie und Pathologische Anatomie bAbteilung für Humangenetik der Christian-Albrecht-Universität Kiel

Related Articles for ""

Onkologie 1986;9:97–107

Log in to MyKarger to check if you already have access to this content.


Buy

  • FullText & PDF
  • Unlimited re-access via MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!


If you would like to redeem your KAB credit, please log in.


Save over 20% compared to the individual article price.

Learn more

Rent/Cloud

  • Rent for 48h to view
  • Buy Cloud Access for unlimited viewing via different devices
  • Synchronizing in the ReadCube Cloud
  • Printing and saving restrictions apply

Rental: USD 8.50
Cloud: USD 20.00

Select

Subscribe

  • Access to all articles of the subscribed year(s) guaranteed for 5 years
  • Unlimited re-access via Subscriber Login or MyKarger
  • Unrestricted printing, no saving restrictions for personal use
read more

Subcription rates


Select
* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: April 24, 2009
Issue release date: 1986

Number of Print Pages: 11
Number of Figures: 0
Number of Tables: 0

ISSN: 2296-5270 (Print)
eISSN: 2296-5262 (Online)

For additional information: https://www.karger.com/ORT

Abstract

T-Zellen-Lymphome sind relativ selten in unserem Untersuchungsgut, sie machen weniger als 20% aller Non-Hodgkin-Lymphome aus. Eine definitive Klassifikation der T-Zellen-Lymphome gibt es noch nicht. Man unterscheidet jedoch schon jetzt thymische und präthymische = lymphoblastische Lymphome von (postthymischen =) peripheren T-Zellen-Lymphomen. Unter den peripheren T-Zellen-Lymphomen sind folgende Subtypen relativ gut definiert: die T-CLL und die T-PLL, die Mycosis fungoides und das Sézary-Syndrom, das lymphoepi-theloide Lymphom (Lennerts Lymphom), das T-Zonen-Lymphom, das T-immunoblastische Lymphom und das anaplastische großzell·ige Lymphom (sog. Kil-Lymphom). Als Lymphogranulomatosis-X(AILD)-Typ wird neuerdings ein T-Zel-len-Lymphom abgegrenzt, das sich von den nichtneoplastischen Lym-phogranulomatosis X-Fällen durch klonale chromosomale Abnor-mitäten und durch Rearrangement der β-Kette des T-Zellen-Rezeptors auszuzeichnen scheint. Histologische und zytochemische Kriterien erlauben in vielen Fallen T-Zellen-Lymphome als solche zu identifizieren. Die Anwendung einer großen Zahl von monoklonalen Antikörpern erbrachte dagegen nicht viel mehr als die Sicherung der T-Zellen-Natur und die Proliferationsrate der Tumorzellen. Mit Hilfe der DNA-Rearrangement-Techniken gelingt es erstmals, polyklonale von monoklonalen T-Zellproliferationen zu unterscheiden. Das lymphoepitheloide Lymphom, der Lymphogranulomatosis-X-Typ und das großzeflige anaplastische Lymphom (Kil Lymphom) werden ausführlicher abgehandelt. Die Grenze von Morbus Hodgkin und peripheren T-Zellen-Lymphomen ist nicht so scharf, wie Lehrbücher glauben machen wollen.

© 1986 S. Karger AG, Basel




Related Articles:


Article / Publication Details

First-Page Preview
Abstract of Paper

Published online: April 24, 2009
Issue release date: 1986

Number of Print Pages: 11
Number of Figures: 0
Number of Tables: 0

ISSN: 2296-5270 (Print)
eISSN: 2296-5262 (Online)

For additional information: https://www.karger.com/ORT


Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
TOP